Related Experiment Video
Updated: Mar 19, 2026
The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice
Published on: November 1, 2015
Systemic lupus erythematosus: still a challenge for physicians
1Rheumatology, Department of Clinical Sciences Lund, Skåne University Hospital, Lund University, Lund, Sweden.
Insights
Systemic lupus erythematosus (SLE) involves immune defects affecting multiple organs, with cardiovascular disease impacting prognosis. Advances reveal key roles for type I interferon and B lymphocyte stimulator (BLyS) in SLE pathogenesis, leading to new targeted therapies like belimumab.
Area of Science:
- Immunology
- Rheumatology
- Genetics
Background:
- Systemic lupus erythematosus (SLE) presents complex clinical features with diverse immune system defects.
- Early cardiovascular disease is a significant factor in SLE prognosis, alongside major organ involvement.
- Recent discoveries have elucidated mechanisms underlying SLE, including apoptotic cell handling and type I interferon pathways.
Purpose of the Study:
- To summarize recent advancements in understanding SLE pathogenesis.
- To highlight the roles of type I interferon and B lymphocyte stimulator (BLyS) in SLE.
- To discuss the implications of new genetic and environmental findings for SLE treatment.
Main Methods:
- Review of recent scientific literature on SLE.
- Analysis of genetic associations with SLE organ manifestations.
- Examination of emerging therapeutic strategies for SLE.
Main Results:
- Defects in apoptotic cell clearance, increased type I interferon gene expression, and autoreactive B cell activation are central to SLE.
- Genetic factors (e.g., STAT4, IRF8) and environmental triggers contribute to SLE.
- The development of targeted therapies, such as BLyS inhibitor belimumab, represents a significant therapeutic advance.
Conclusions:
- Increased understanding of SLE mechanisms has driven the development of novel treatments.
- Targeting key pathways like BLyS offers promising therapeutic avenues for SLE patients.
- Ongoing research continues to identify genetic and environmental factors influencing SLE and its manifestations.
Abstract:
Systemic lupus erythematosus (SLE) has a complex clinical picture, and a number of defects in the immune system have been described in patients with the disease. Most organs can be involved in SLE, and in addition to the typical major organ manifestations (e.g. from kidneys and the central nervous system), early cardiovascular disease is a major determinant of prognosis. Several important findings during the last decade have increased the understanding of the mechanisms behind the disease characteristics and the underlying autoimmune process. Amongst, these are defects in the handling of apoptotic cells, increased expression of type I interferon-regulated genes and activation of autoreactive B cells, with both the type I interferon system and the B lymphocyte stimulator (BLyS) having key roles. In addition, a large number of genes have been identified that contribute to these abnormalities. It has also become clear that certain SLE risk genes are associated with some organ manifestations, such as STAT4 with nephritis and IRF8 with myocardial infarction. Furthermore, environmental factors that can induce SLE or trigger a disease flare have been identified. As a consequence of this increased knowledge, new treatments for SLE have been developed. The most recently approved drug for SLE is belimumab, which blocks BLyS, and several new therapies and therapeutic strategies are in the pipeline for clinical application.
Related Concept Videos
01:26Nephrotic Syndrome II : Assessment and Medical Management
01:29Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune...
01:24Nephrotic Syndrome I : Introduction